Literature DB >> 10997166

A randomized double-blind sham-controlled study of intrathecal human anti-tetanus immunoglobulin in the management of tetanus.

M Agarwal1, K Thomas, J V Peter, L Jeyaseelan, A M Cherian.   

Abstract

BACKGROUND: Tetanus is a major cause of mortality and morbidity in developing countries. Various modalities of treatment to prevent progression of the disease and alter its outcome have been tried. This study was designed to evaluate the role of intrathecal human anti-tetanus immunoglobulin (TIG) in the management of tetanus.
METHODS: Thirty-six adult patients presenting to an university-affiliated teaching hospital were stratified based on the severity of disease into mild and severe disease, and subsequently randomly allocated to receive either 250 i.u. of TIG intrathecally or a sham procedure mimicking the lumbar puncture.
RESULTS: In mild tetanus, TIG administration significantly retarded the rate of progression (p = 0.05), reduced the duration of hospital (p = 0.01) and intensive care unit stay (p = 0.05), need for tracheostomies (p = 0.03) and the dose of sedatives required for control of spasms (p = 0.01). In mild tetanus, the mortality rates were 20% and 30% in the treated and control groups, respectively.
CONCLUSION: We suggest that TIG is useful in reducing the morbidity, progression of disease and mortality in patients presenting with mild tetanus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10997166

Source DB:  PubMed          Journal:  Natl Med J India        ISSN: 0970-258X            Impact factor:   0.537


  6 in total

1.  Human versus equine intramuscular antitoxin, with or without human intrathecal antitoxin, for the treatment of adults with tetanus: a 2 × 2 factorial randomised controlled trial.

Authors:  Nguyen Van Hao; Huynh Thi Loan; Lam Minh Yen; Evelyne Kestelyn; Duc Du Hong; Duong Bich Thuy; Nguyen Thanh Nguyen; Ha Thi Hai Duong; Tran Thi Diem Thuy; Phung Tran Huy Nhat; Phan Nguyen Quoc Khanh; Nguyen Thi Phuong Dung; Nguyen Hoan Phu; Nguyen Thanh Phong; Pham Thi Lieu; Pham Thi Tuyen; Bui Thi Bich Hanh; Ho Dang Trung Nghia; Pham Kieu Nguyet Oanh; Phan Vinh Tho; Tran Tan Thanh; Hugo C Turner; H Rogier van Doorn; Le Van Tan; Duncan Wyncoll; Nicholas Pj Day; Ronald B Geskus; Guy E Thwaites; Nguyen Van Vinh Chau; C Louise Thwaites
Journal:  Lancet Glob Health       Date:  2022-06       Impact factor: 38.927

2.  Elimination of maternal and neonatal tetanus: a 21st-century challenge.

Authors:  Sharon Owusu-Darko; Khady Diouf; Nawal M Nour
Journal:  Rev Obstet Gynecol       Date:  2012

3.  Randomised controlled trial of tetanus treatment with antitetanus immunoglobulin by the intrathecal or intramuscular route.

Authors:  Demócrito de Barros Miranda-Filho; Ricardo Arraes de Alencar Ximenes; Antônio Alci Barone; Vicente Luiz Vaz; Aderbal Gomes Vieira; Valéria Maria Gonçalves Albuquerque
Journal:  BMJ       Date:  2004-03-05

4.  Intrathecal tetanus immunoglobulins in the management of tetanus.

Authors:  M G Geeta; P Krishnakumar; Lulu Mathews
Journal:  Indian J Pediatr       Date:  2007-01       Impact factor: 5.319

5.  A Pilot Study to Assess Safety and Feasibility of Intrathecal Immunoglobulin for the Treatment of Adults with Tetanus.

Authors:  Huynh Thi Loan; Lam Minh Yen; Evelyne Kestelyn; Nguyen Van Hao; Nguyen Thi Hoang Mai; Duong Bich Thuy; Ha Thi Hai Duong; Nguyen Thi Phuong Dung; Nguyen Hoan Phu; Pham Thi Lieu; Tran Tan Thanh; Ronald Geskus; H Rogier van Doorn; Le Van Tan; Duncan Wyncoll; Nicholas P J Day; Tran Tinh Hien; Guy E Thwaites; Nguyen Van Vinh Chau; C Louise Thwaites
Journal:  Am J Trop Med Hyg       Date:  2018-06-14       Impact factor: 2.345

6.  Intrathecal Immunoglobulin for treatment of adult patients with tetanus: A randomized controlled 2x2 factorial trial.

Authors:  Huỳnh Thị Loan; Lam Minh Yen; Evelyne Kestelyn; Nguyen Van Hao; Tran Tan Thanh; Nguyen Thi Phuong Dung; Hugo C Turner; Ronald B Geskus; Marcel Wolbers; Le Van Tan; H Rogier Van Doorn; Nicholas P Day; Duncan Wyncoll; Tran Tinh Hien; Guy E Thwaites; Nguyen Van Vinh Chau; C Louise Thwaites
Journal:  Wellcome Open Res       Date:  2018-11-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.